Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115095
Chunk: 257

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 257
---
 P=0.001 |     |              |

| (1) | Censored patients are the following: (1) patients who do not receive a repeat injection of SP-102 and (2) patients who discontinued the study prior to Week 20 without receiving a repeat injection. |

| (2) | Quartiles are estimated using Kaplan-Meier estimation. |

| (3) | A Cox proportional hazards model was utilized to test the treatment difference while adjusting for site and Pain Catastrophizing Scale (<30 or ≥30). |

CI: confidence interval; ITT: intent-to-treat(randomized population); SD: standard deviation 165

Responder Analysis (Change from Baseline in Mean NPRS, Average Daily Pain in Affected Leg) (1)– ITT Population

|                                              |     | SP-102            
 N=202             |     | Placebo    
 N=199      |
| 30% reduction                                |     | 88 (43.6%)        |     | 57 (28.6%) |
| Chi-Square                                   |     | P=0.002           |     |            |
| Logistic regression(2) (odds ratio [95% CI]) |     | 1.96 (1.28, 2.98) |     |            |
|                                              |     | P=0.002           |     |            |
| 50% reduction                                |     | 58 (28.7%)        |     | 41 (20.6%) |
| Chi-Square                                   |     | P=0.060           |     |            |
| Logistic regression(2) (odds ratio [95% CI]) |     | 1.58 (0.99, 2.52) |     |            |
|                                              |     | P=0.055           |     |            |

| (1) | Patients that discontinued or have missing scores at Week Four were considered non-responders. |

| (2) | Logistic regression models with treatment (SP-102 or placebo), site, and Pain Catastrophizing Scale group (<30 or ≥30), and baseline averaged daily pain score as factors were used to compare the treatment groups at each week. |

CI: confidence interval; ITT: intent-to-treat(randomized population) Phase 2 Repeat Dose Study- SP-102-03 We conducted an open-label, single-arm,pharmacodynamics (“PD”) and tolerability study of repeat epid